Clinical Trial Results Support Use of Weekly Extended-Release Buprenorphine for Treatment of Opioid Use Disorder During Pregnancy

Why It Matters

Improved abstinence and fewer serious maternal events can lower overdose risk and enhance treatment continuity for pregnant patients, influencing clinical guidelines and payer policies.

Key Takeaways

• Weekly injectable buprenorphine improves abstinence rates in pregnant patients
• Serious maternal adverse events lower versus sublingual formulation
• Neonatal withdrawal outcomes unchanged between treatment groups
• Trial involved 140 pregnant adults across multiple centers
• Findings support FDA consideration for extended‑release use in pregnancy

Pulse Analysis

Opioid use disorder (OUD) remains a leading cause of maternal morbidity, with untreated cases jeopardizing both mother and infant. Traditional sublingual buprenorphine, while effective, suffers from daily dosing burdens, peak‑trough fluctuations, and potential misuse, which can erode adherence during pregnancy. Health systems therefore seek longer‑acting formulations that maintain steady plasma levels, reduce diversion risk, and simplify care coordination for obstetric providers. The extended‑release injectable, already approved for non‑pregnant adults, offers a promising pharmacologic bridge that aligns with these clinical imperatives.

The NIH‑supported trial, part of the HEAL Initiative, randomized participants to weekly injectable or daily sublingual buprenorphine across several academic sites. Urine drug screens revealed a statistically significant increase in opioid‑negative results for the injectable group, and serious maternal adverse events were notably fewer, suggesting a safer profile during gestation. Importantly, neonatal opioid withdrawal syndrome rates did not differ, indicating that the longer‑acting drug does not exacerbate infant outcomes. These data provide robust evidence for clinicians to consider extended‑release buprenorphine as a first‑line option, especially for patients struggling with daily adherence or at high risk of relapse.

Beyond the trial, the results could reshape policy and reimbursement landscapes. Regulators may expedite labeling updates, while insurers might expand coverage to include injectable formulations for pregnant patients, reducing out‑of‑pocket barriers. Obstetric programs can integrate the weekly injection into prenatal visits, streamlining multidisciplinary care and potentially decreasing overall healthcare costs associated with overdose and neonatal intensive care. Future research should explore postpartum dosing schedules, breastfeeding safety, and long‑term child development outcomes, cementing extended‑release buprenorphine’s role in a comprehensive public‑health response to the opioid crisis.